|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400085183 |
|
最近更新日期: Date of Last Refreshed on: |
2024-06-03 09:44:40 |
|
注册时间: Date of Registration: |
2024-06-03 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
基于二元应对的PCI术后患者心脏运动康复干预效果研究 |
|
Public title: |
Effectiveness of a Binary Coping-Based Intervention on Cardiac Exercise Rehabilitation in Post-Percutaneous Coronary Intervention (PCI) Patients |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于二元应对的PCI术后患者心脏运动康复干预效果研究 |
|
Scientific title: |
Effectiveness of a Binary Coping-Based Intervention on Cardiac Exercise Rehabilitation in Post-Percutaneous Coronary Intervention (PCI) Patients |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
黄靖涓 |
研究负责人: |
黄靖涓 |
|
Applicant: |
Huang Jingjuan |
Study leader: |
Huang Jingjuan |
|
申请注册联系人电话: Applicant telephone: |
+86 158 9968 8105 |
研究负责人电话: Study leader's telephone: |
+86 158 9968 8105 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
405583816@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
405583816@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省东莞市万江街道新谷涌万道路78号 |
研究负责人通讯地址: |
广东省东莞市万江街道新谷涌万道路78号 |
|
Applicant address: |
78, Wandao Street, Wanjiang Road, Dongguan, Guangdong Province, China |
Study leader's address: |
78, Wandao Street, Wanjiang Road, Dongguan, Guangdong Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
东莞市人民医院 |
||
|
Applicant's institution: |
Dongguan People's Hospital |
||
|
研究负责人所在单位: |
东莞市人民医院 |
||
|
Affiliation of the Leader: |
Dongguan People's Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KYKT2023-48 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
东莞市人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Dongguan People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-10-07 00:00:00 |
||
|
伦理委员会联系人: |
袁领勤 |
||
|
Contact Name of the ethic committee: |
Yuan Lingqin |
||
|
伦理委员会联系地址: |
广东省东莞市万江街道新谷涌万道路78号 |
||
|
Contact Address of the ethic committee: |
78, Wandao Street, Wanjiang Road, Dongguan, Guangdong Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 769 2863 6365 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
东莞市人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Dongguan People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省东莞市万江街道新谷涌万道路78号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
78, Wandao Street, Wanjiang Road, Dongguan, Guangdong Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
none |
||||||||||||||||||||||
|
Target disease: |
coronary heart disease |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
单病例随机对照研究 |
||||||||||||||||||||||
|
Study design: |
N of 1 Trial |
||||||||||||||||||||||
|
研究目的: |
1.构建二元应对的 PCI 术后患者心脏运动康复方案。 2.通过实施二元应对的PCI术后患者心脏运动康复方案,探索二元应对的心脏运动康复方案对改善PCI术后患者心脏运动康复依从性、左心功能及生活质量的效果。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Construct a dual response cardiac exercise rehabilitation program for patients after PCI. 2. Through the implementation of the dual response cardiac exercise rehabilitation program for patients after PCI, explore the effect of the dual response cardiac exercise rehabilitation program on improving the compliance of cardiac exercise rehabilitation, left heart function and quality of life of patients after PCI. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
患者:①年龄20-75周岁;②符合 WHO 冠心病的诊断标准,且经皮冠状动脉介入术植入 1-2 枚支架的患者;③冠状动脉单支病变;④术后LVEF≥40%,心功能分级Ⅰ-Ⅱ级的患者;⑤心率55-100次/分,收缩压90-140mmHg,舒张压60-90mmHg;⑥无言语不利,无精神疾病,可以正常交流,肢体功能健全、活动自如;⑦已婚且与配偶共同生活;患者及配偶同意并积极配合运动康复治疗者;⑧经桡动脉、尺动脉穿刺的患者;⑨会使用智能手机微信功能。 配偶:①年龄≥20周岁,小学及以上文化程度;②意识清晰,无视力、听力及沟通障碍;③会使用智能手机微信功能;④知晓本研究方法并愿意参与者。 |
||||||||||||||||||||||
|
Inclusion criteria |
Patients: ① 20-75 years old; ② Patients WHO meet the diagnostic criteria for coronary heart disease and have 1-2 stents implanted by percutaneous coronary intervention; ③ single-vessel coronary artery disease; ④ Patients with postoperative LVEF≥40% and cardiac function grade I-II; ⑤ Heart rate 55-100 times/min, systolic blood pressure 90-140mmHg, diastolic blood pressure 60-90mmHg; ⑥ no speech, no mental illness, can communicate normally, body function is sound, free movement; ⑦ Married and living with spouse; The patient and his spouse agree and actively cooperate with the exercise rehabilitation treatment; ⑧ Patients with puncture through radial artery or ulnar artery; ⑨ Use wechat on your smartphone. Spouse: ① ≥20 years old, primary school education or above; ② Clear consciousness, no vision, hearing and communication disorders; ③ Can use wechat function of smart phone; Be aware of the study method and willing to participate. |
||||||||||||||||||||||
|
排除标准: |
患者:①术后出现严重并发症,如恶性心律失常、心包填塞、急性心衰、支架内急性血栓形成、血流动力学不稳定者;②合并恶性肿瘤、其他重要脏器严重功能障碍者;③参加其他相关康复治疗或研究者。 配偶:患有严重疾病或由于其他原因无法配合本研究者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Patients: ① Serious complications occurred after surgery, such as malignant arrhythmia, pericardial tamponade, acute heart failure, acute stent thrombosis, and hemodynamic instability; ② Patients with malignant tumors and serious dysfunction of other important organs; ③ Participate in other related rehabilitation therapy or researchers. Spouse: has a serious illness or is unable to cooperate with the investigator for other reasons. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-09-01 00:00:00至 To 2024-06-07 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-09-06 00:00:00 至 To 2023-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机对照干预研究。通过便利抽样法选取东莞市某三甲医院心血管内科2023年9月至12月行经皮冠脉动脉介入术(Percutaneous Coronary Intervention,PCI)术后且符合纳排的76例患者,并随机分配分为对照组38例和试验组38例。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Randomized controlled intervention study. By objective sampling method, 76 patients receiving Percutaneous Coronary Intervention (PCI) after coronary intervention in the cardiovascular department of a Grade-A hospital in Dongguan City from July to October 2023 were selected, and randomly assigned into the control group (38 cases) and the experimental group (38 cases). |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
双盲,对收集数据者及数据分析者设盲。 |
|
Blinding: |
Double blind, Blind data collectors and data analysts. |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
ResMan;http://www.medresman.org.cn/login.aspx |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
ResMan; http://www.medresman.org.cn/login.aspx |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
ResMan;http://www.medresman.org.cn/login.aspx |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
ResMan;http://www.medresman.org.cn/login.aspx |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |